Plains GP Holdings (PAGP) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Achieved strong 2024 financial results: Adjusted EBITDA of $2.78B (4% above guidance), $1.17B in adjusted free cash flow, and returned $1.15B to equity holders via distributions.
Completed seven accretive bolt-on acquisitions for ~$800M, extended contract terms in the Permian, and maintained a leverage ratio of ~3.0x, below target range.
Increased annual distribution by 19% in 2024 and 20% in early 2025, with total unitholder returns of 21% (PAA) and 24% (PAGP) in 2024.
Received a Moody’s credit rating upgrade to Baa2, achieving investment grade ratings from all three agencies.
Entered 2025 with momentum, focusing on capital discipline, cash flow generation, and value creation in a constructive but volatile energy environment.
Voting matters and shareholder proposals
Shareholders will vote on: (1) election of four Class II directors until 2028, (2) ratification of PricewaterhouseCoopers LLP as independent auditor for 2025, and (3) non-binding advisory approval of 2024 named executive officer compensation.
Board recommends voting FOR all director nominees and FOR proposals 2 and 3.
Shareholders as of March 24, 2025, are eligible to vote; voting can be done online, by phone, mail, or in person at the May 21, 2025 meeting.
Board of directors and corporate governance
Unified governance structure with a single board responsible for both PAA and PAGP; all directors now subject to public election.
Board consists of 11 members, majority independent (8 of 11), with a Lead Director role rotating every five years.
Four standing committees: Audit, Compensation, Governance, and Health, Safety, Environmental & Sustainability (HSES), all comprised of independent directors.
Board succession planning, annual self-assessments, and director evaluations are in place.
Shareholders have limited voting rights but can elect directors and submit proposals under defined conditions.
Latest events from Plains GP Holdings
- Exceeded guidance, raised distributions, and forecasted growth driven by acquisitions and Permian strength.PAGP
Q4 20249 Feb 2026 - Q2 2024 Adjusted EBITDA beat expectations; full-year guidance raised on strong execution.PAGP
Q2 20249 Feb 2026 - 2025 EBITDA reached $2.83B; 2026 targets $2.75B, with higher distributions and cost savings.PAGP
Q4 20256 Feb 2026 - Q3 Adjusted EBITDA $659M, leverage 3.0x, and Moody's upgrade support strong 2024 outlook.PAGP
Q3 202415 Jan 2026 - Director elections, auditor ratification, and executive pay are up for vote at the 2025 meeting.PAGP
Proxy Filing2 Dec 2025 - Q1 2025 net income up 67%, Adjusted EBITDA $754M, strong growth and strategic acquisitions.PAGP
Q1 202526 Nov 2025 - Q2 Adjusted EBITDA $672M; NGL sale and acquisitions boost financial flexibility and focus.PAGP
Q2 202523 Nov 2025 - Q3 2025 EBITDA hit $669M; net income doubled, with acquisitions and NGL sale refocusing strategy.PAGP
Q3 202513 Nov 2025 - Raised 2024 EBITDA guidance and delivered strong free cash flow with efficient growth.PAGP
Investor Reception Presentation25 Jun 2025